Financial Services -
Asset Management - NASDAQ - US
$ 2.14
-0.469 %
$ 35.5 M
Market Cap
-17.67
P/E
1. INTRINSIC VALUE
Balance Sheet
Binah Capital Group, Inc.
| Current Assets | 19.5 M |
| Cash & Short-Term Investments | 7.49 M |
| Receivables | 11 M |
| Other Current Assets | 1 M |
| Non-Current Assets | 47.2 M |
| Long-Term Investments | 0 |
| PP&E | 4.33 M |
| Other Non-Current Assets | 42.9 M |
| Current Liabilities | 21.7 M |
| Accounts Payable | 21.7 M |
| Short-Term Debt | 0 |
| Other Current Liabilities | 0 |
| Non-Current Liabilities | 43.8 M |
| Long-Term Debt | 28.8 M |
| Other Non-Current Liabilities | 14.9 M |
EFFICIENCY
Earnings Waterfall
Binah Capital Group, Inc.
| Revenue | 164 M |
| Cost Of Revenue | 152 M |
| Gross Profit | 11.9 M |
| Operating Expenses | 10.4 M |
| Operating Income | 1.48 M |
| Other Expenses | 6.04 M |
| Net Income | -4.56 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Binah Capital Group, Inc.
| Net Income | -4.56 M |
| Depreciation & Amortization | 1.02 M |
| Capital Expenditures | -85 K |
| Stock-Based Compensation | 0 |
| Change in Working Capital | 314 K |
| Others | 1.3 M |
| Free Cash Flow | -702 K |
Wall Street Analysts Price Targets
Binah Capital Group, Inc.
BCG has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
BCG does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Binah Capital Group, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
CORRECTION - Binah Capital Group Announces PKS Investments as Finalist in Two Categories for the 2025 Wealth Management Industry Awards
- Dual Recognition Underscores Binah's Unmatched Commitment to Leadership and Operational Excellence - - Dual Recognition Underscores Binah's Unmatched Commitment to Leadership and Operational Excellence -
globenewswire.com
- 1 month ago
Binah Capital Group Announces PKS Investments as Finalist in Two Categories for the 2025 Wealth Management Industry Awards
- Dual Recognition Underscores Binah's Unmatched Commitment to Leadership and Operational Excellence - - Dual Recognition Underscores Binah's Unmatched Commitment to Leadership and Operational Excellence -
globenewswire.com
- 1 month ago
Binah Capital Group Reports First Quarter 2025 Results
- Grew Total Revenue 18% Year-over-Year to $49 Million - - Assets Under Management (“AuM”) Increased 3% Year-over-Year to $26 Billion - - Net Income of $1 Million - - Increased EBITDA 1 to $2.2 Million from $(0.0) Million in the Prior Year - NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Binah Capital Group, Inc. (“Binah”, “Binah Capital” or the “Company”) (NASDAQ: BCG; BCGWW), a leading financial services enterprise that owns and operates a network of industry-leading firms empowering independent financial advisors, today announced results for the quarter ended March 31, 2025. "We once again delivered strong results, which is a continued testament to our differentiated RIA platform,” stated Craig Gould, Chief Executive Officer of Binah Capital Group.
globenewswire.com
- 2 months ago
IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca's IMFINZI® (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) compared to BCG induction and maintenance therapy alone. The trial was not statistically pow.
businesswire.com
- 2 months ago
Binah Capital Group Expands Executive Team with Appointment of Industry Veteran Ryan Marcus as Chief Business Development and Engagement Officer
- Will Contribute to Development and Implementation of Long-Term Business Strategy - - Will Contribute to Development and Implementation of Long-Term Business Strategy -
globenewswire.com
- 2 months ago
Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced positive long-term results from its QUILT-3.032 study of ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS), with or without papillary disease. The findings were shared during an oral presentation at the American Urological.
businesswire.com
- 2 months ago
Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC
First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumours, demonstrating the potential for bladder preservation with 94 percent of patients avoiding radical cystectomy 1
globenewswire.com
- 2 months ago
Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC
First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumors, demonstrating the potential for bladder preservation with 94 percent of patients avoiding radical cystectomy 95 percent progression-free survival rate at 9-months signals the promise of TAR-200 in this high-risk patient population LAS VEGAS , April 26, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced first results from Cohort 4 of the Phase 2b SunRISe-1 study evaluating TAR-200—an intravesical gemcitabine releasing system—for patients with certain types of bladder cancer. These first results show the promise of TAR-200 in this patient population with more than an 80 percent disease-free survival (DFS) rate without the need for reinduction and 94 percent of patients able to preserve their bladder.
prnewswire.com
- 2 months ago
Binah Capital Group's David Shane Recognized Among Top 5 Wealth Management CFOs by Wealth Solutions Report
NEW YORK, April 09, 2025 (GLOBE NEWSWIRE) -- Binah Capital Group, Inc. ("Binah" or “the Company”) (NASDAQ: BCG; BCGWW), a leading financial services enterprise that owns and operates a network of industry-leading firms empowering independent financial advisors, proudly announces that its Chief Financial Officer (“CFO”), David Shane, has been named one of the Top 5 Wealth Management CFOs by Wealth Solutions Report in their annual "CFO 5" list. This prestigious recognition highlights CFOs who have demonstrated exceptional leadership and strategic vision in the financial services industry.
globenewswire.com
- 3 months ago
Binah Capital Group Reports Fourth Quarter and Full Year 2024 Results
- Grew Total Revenue 8% Year-over-Year to $45 Million in the Fourth Quarter 2024 - - Assets Under Management (“AuM”) Increased 13% Year-over-Year to $27 Billion - - GAAP Net Loss of $1.1 Million in the Fourth Quarter - - Grew Adjusted EBITDA * 43% Year-Over-Year to $2.0 Million in the Fourth Quarter - NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Binah Capital Group, Inc. (“Binah”, “Binah Capital” or the “Company”) (NASDAQ: BCG; BCGWW), a leading financial services enterprise that owns and operates a network of industry-leading firms empowering independent financial advisors, today announced results for the quarter and year ended December 31, 2024. "As we celebrate the one-year anniversary of our successful public listing, we're pleased to deliver our 2024 fourth quarter results,” stated Craig Gould, Chief Executive Officer of Binah Capital Group.
globenewswire.com
- 3 months ago
Altice USA to Present at the 2025 New Street Research and BCG Future of Connectivity Leaders Conference
NEW YORK--(BUSINESS WIRE)--Altice USA (NYSE: ATUS) today announces that Dennis Mathew, Chairman and CEO, will present at the New Street Research and BCG Future of Connectivity Leaders Conference on Wednesday, March 26, 2025, at 11:35 a.m. Eastern Time. A live webcast will be available online on the Altice USA investor relations website or by following this link. Date: Wednesday, March 26, 2025 Time: 11:35 a.m. Eastern Time Presenter: Dennis Mathew, Chairman & CEO About Altice USA Altice USA.
businesswire.com
- 4 months ago
New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer
Application accepted for U.S. FDA Real-Time Oncology Review (RTOR) based on Phase 2b SunRISe-1 study showing highest single-agent complete response rate of 83.5 percent1 RARITAN, N.J. , Jan. 15, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced it has initiated the submission of an original New Drug Application with the U.S. Food and Drug Administration (FDA) for TAR-200 for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.
prnewswire.com
- 6 months ago
8. Profile
Summary
Binah Capital Group, Inc. BCG
COUNTRY
US
INDUSTRY
Asset Management
MARKET CAP
$ 35.5 M
Dividend Yield
0.55%
Description
Binah Capital Group, Inc., together with its subsidiaries, operates in the wealth management industry. The company provides access to stock, bond, exchange-traded fund, and options execution services; and research, compliance, supervision, and accounting and related services for financial advisors. It also offers mutual funds and insurance products, as well as alternative investments, such as non-traded real estate investment trusts, unit trusts, and fixed and variable annuities. The company was founded in 2016 and is headquartered in Albany, New York. Binah Capital Group, Inc. operates as a subsidiary of MHC Securities, LLC.
Contact
80 State Street, Albany, NY, 12207
https://www.wentworthms.com
IPO
Date
March 27, 2024
Employees
150
Officers
Mr. Craig Michael Gould
Chief Executive Officer & Chairman of the Board
Ms. Kathrine Flouton
President & Chief Executive Officer of Purshe Kaplan Sterling Investments, Inc.
Mr. Ryan Marcus
Chief Business Development & Engagement Officer
Mr. David Shane
Chief Financial Officer & Director
Mr. Roger Farrell Leibowitz
Chief Financial Officer of Cabot Lodge Securities, LLC